Vaxcyte Q3 net loss $92.7M; FDA clears VAX-31 IND; VAX-24 Phase 3 agreed

Vaxcyte, Inc.

2023-Q3 EPS reported -$2.32

Net loss $92.7M vs $57.9M YoY; cash $1.43B (up from $957.9M Dec 2022).
Completed End-of-Phase 2 FDA meeting for VAX-24 adult Phase 3; topline data expected 2025.
FDA cleared VAX-31 adult IND; Phase 1/2 starts Q4 2023, topline data H2 2024.
Expanded Lonza collaboration for commercial manufacturing of VAX-24 and VAX-31.
VAX-24 infant Phase 2 advanced to Stage 2 with comparator Prevnar 20.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.